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Abstract: Low homoarginine is an independent marker of mortality in heart failure patients and
incident cardiovascular events. Whether homoarginine is related with healthier cardiac structure
and function is currently unclear. We used data of the population-based “Study of Health in
Pomerania” (SHIP-Trend) to assess this relation. Homoarginine was measured in serum using
liquid chromatography-tandem mass spectrometry. Linear regression models assessed the relation
between homoarginine and several structural as well as functional parameters and N-terminal pro
B-type natriuretic peptide (NTproBNP). All models were adjusted for age, sex, body mass index,
and renal function. A total of 3113 subjects (median age 48 (25th percentile 37 to 75th percentile 60)
years, 46% male) were included. A standard deviation decrease in homoarginine was associated
with a larger left ventricular diastolic diameter (0.3; 95%-confidence interval (CI): 0.2 to 0.5 mm;
p < 0.001), left ventricular systolic diameter (0.38; 95%-CI: −0.22 to 0.54 mm; p < 0.001) as well as
a less relative wall thickness (–0.003 95%-CI: −0.006 to −0.0008; p = 0.01), left ventricular ejection
fraction (–0.47; 95%-CI: –0.79 to −0.15%; p < 0.01) and fractional shortening (−0.35; 95%-CI: −0.62 to
0.07%; p = 0.01). Low homoarginine was also related to higher NTproBNP (−0.02 95%-CI: −0.034 to
−0.009 log pg/mL; p < 0.01). Lower serum homoarginine is associated with dilatation of the heart
and decreased function. Prospective clinical studies should assess if homoarginine supplementation
improves cardiac health in subjects with low serum concentrations.
Keywords: homoarginine; echocardiography; population-based
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1. Introduction
L-arginine (Arg) is a semi-essential amino acid with a vital role in living organisms, being part
of several metabolic pathways [1]. For example, Arg is a substrate for the synthesis of nitric oxide
(NO) by NO synthase (NOS). In addition, arginase catalyzes the conversion of Arg to ornithine,
keeping the urea cycle in motion. Further, arginine:glycine amidinotransferase (AGAT) catalyzes the
formation of L-homoarginine (hArg) from Arg [2]. Even though hArg may serve as an alternative
substrate for NO and inhibits arginase in a similar extend compared to lysine, its low physiological
concentration and affinity to enzymes make hArg unlikely to play a significant role in the physiology
of the NO pathway [3,4].
Nevertheless, recent experimental and clinical data indicate a potential role of hArg in
cardiovascular disease (CVD), since hArg deficiency or impairment is associated with adverse
outcomes [5–8]. Specifically, low hArg was related with myocardial dysfunction and a higher risk
of CVD mortality in patients referred to coronary angiography [9], patients with ischemic stroke [8],
elderly subjects from the general population [10], as well as in a large German cohort with dialysis
patients [5,11]. Low serum hArg concentrations were also related to an increased risk for all-cause
and CVD mortality. In patients with chronic heart failure circulating hArg was associated with
biochemical (N-terminal pro B-type natriuretic peptide [NTproBNP]) as well as clinical characteristics
(NYHA classification) of heart failure. Furthermore, low hArg was an independent marker of all-cause
mortality in this cohort [12].
Very few clinical studies have explored the relation between circulating hArg and left ventricular
cardiac remodeling. Results from the “Diagnostic Trial on Prevalence and Clinical Course of Diastolic
Dysfunction and Diastolic Heart Failure” (DIAST-CHF) study showed that low hArg was related
with higher NTproBNP and presence of diastolic dysfunction [6]. We aimed to extend the current
knowledge by assessing the relation between left and right ventricular structural and functional
parameters with hArg in a general population-based cohort from northeast Germany.
2. Materials and Methods
2.1. Study Population
The presented data were derived from the population-based cohort study “Study of Health in
Pomerania (SHIP) in Germany” [13]. In brief, from the total population of West Pomerania, a rural
area in the northeastern part of Germany, a two-stage stratified cluster sample of 8016 adults between
the ages of 20–79 years was drawn (SHIP-TREND). In total, 4420 individuals participated in the
study (response of 50.1%). Data used in this analysis are based on data collected during the baseline
examination of SHIP-TREND, which took place between 2008 and 2011. The study was approved by
the ethics committee of the University of Greifswald, complies with the Declaration of Helsinki, and all
study participants gave written informed consent. SHIP data are publically available for scientific and
quality control purposes. Data usage can be applied for via www.community-medicine.de.
For the present analysis, individuals with severely impaired renal function (estimated glomerular
filtration rate (eGFR) < 30 mL/min/1.73 m2), previous myocardial infarction, left ventricular ejection
fraction < 40%, atrial fibrillation, extreme values for hArg (<0.995 percentile), and missing data were
excluded. The total sample size was 3113 subjects.
2.2. Interview, Medical, and Laboratory Examination
Trained and certified staff used standardized computer-assisted interviews to assess
sociodemographic and medical characteristics. Smoking was classified as current smoker, nonsmoker,
or former smoker. Previous myocardial infarction was defined as self-reported physician’s diagnosis.
Diabetic patients were identified based on the self-reported use of antidiabetic medication (anatomic,
therapeutic, and chemical (ATC) code: A10) in the last 7 days or a glycosylated hemoglobin level
>6.5%. All participants underwent an extensive standardized medical examination. Anthropometric
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measurements included height and weight based on recommendations of the World Health
Organization (WHO) [14]. Body mass index (BMI) was calculated by dividing weight (kg) by height
(cm) to the square. Blood pressure (BP) was assessed after a 5 min resting period in sitting position.
Systolic and diastolic BP were measured three times, with three minutes rest in-between, on the
right arm, using a digital blood pressure monitor (HEM-705CP, Omron Corporation, Tokyo, Japan).
The average of the second and third reading was used. Hypertensive patients were identified by either
self-reported antihypertensive medication (ATC: C02) or a systolic BP above 140 mmHg and/or a
diastolic value of more than 90 mmHg.
Fasting venous blood samples were drawn from all subjects in supine position (between 7 am
and 4 pm). The eGFR was calculated according to Levey et al. (eGFR = 186 × (plasma creatinine
concentration × 0.0113118)−1.154 × age−0.203) multiplied by 0.742 for female subjects and expressed
as mL/min/1.73 m2 [15]. Serum hArg was quantified by liquid chromatography-tandem mass
spectroscopy (LC-MS/MS) analysis as previously reported [16]. Briefly, 25 µL of serum aliquots
was diluted in methanol with stable isotope-labeled hArg, which was used as internal standard.
Proteins were converted into their butyl ester derivatives, and subsequently subjected to mass
spectrometric analysis.
2.3. Ultrasound Measurements
Two-dimensional, M-mode and Doppler echocardiography were performed using the Vingmed
CFM 800A system (GE Medical Systems, Waukesha, WI, USA) as described in detail elsewhere [17].
Measurements of LV end-diastolic and end-systolic diameter (LVD, LVS) and septal and posterior
wall thickness (SWT, PWT) were performed according to the guidelines of the American Society of
Echocardiography [18]. LV mass (LVM) was calculated according to the formula: LVM (g) = 0.8 ×
(1.04 × ((LVDD + SWT + PWT)3 − LVDD3)) + 0.6 g as described by Devereux and Reichek [19,20].
LVM was indexed (LVMI) for body surface area (BSA) according to Duboi (BSA = 0.20247 × height
(m)0.725 × weight (kg)0.425) [21], which linearizes the relations between LVM and height and identifies
the impact of obesity. LV wall thickness (WT), relative wall thickness (RWT), and LV ejection fraction
(EF) were calculated following the formulas below according to the guidelines of the American Society
of Echocardiography [22]:
WT (cm) = (SWT + PWT)/2.
RWT = WT/LVDD.
EF (%) = (LVDV − LVSV)/LVDV.
Transmitral and transcuspid pulsed-wave Doppler were used to record early (E) and late (A) wave
ventricular filling velocities. Tricuspid annular plane systolic excursion (TAPSE) is a parameter of right
ventricular function. TAPSE was assessed using the four-chamber view in M-mode. Movement of the
lateral tricuspid valve was measured from end-diastole to end-systole. Certification examinations for
interobserver variations revealed an agreement of >90% [17].
2.4. Statistics
Continuous data are expressed as median and 25th/75th percentile. Nominal data are expressed as
percentages. Differences between groups were calculated using Kruskal–Wallis (continuous variables)
and χ2 test (nominal variables), respectively. First, a linear regression adjusted for sex, age, BMI,
and eGFR was fitted to assess the relation between hArg and echocardiographic parameters, as well
as NTproBNP continuously. Furthermore, restricted cubic splines [23] were used to detect possible
nonlinear dependencies of hArg on the investigated echocardiographic parameters. Three knots were
prespecified, located at the 5th, 50th, and 95th percentiles [23], resulting in one component of the spline
function. A p < 0.05 was considered statistically significant. All statistical analyses were performed in
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SAS 9.4 (SAS Institute Inc., Cary, NC, USA). All continuous descriptive characteristics are presented as
median and first as well as third quartile unless otherwise indicated.
3. Results
3.1. Population Description
The population characteristics are provided in Table 1. Briefly, the median age was 48 (37 to 60)
years and 46% were male. Study participants had a median BMI of 26.7 (23.9 to 30.0) kg/m2 and an
eGFR of 89 (77 to 102) mL/min/1.73 m2. Diabetes type 2, hypertension, and metabolic syndrome were
present in 7%, 40%, and 23% of the study population, respectively. The echocardiographic parameters
are grouped according to left and right ventricle, as well as structural and functional parameters.
Table 1. Study population.
Parameter Median (25th and 75th Percentile) or %
Age (years) 48 (37, 60)
Sex (% male) 45.5
Systolic blood pressure (mmHg) 125 (113, 137)
Body mass index (BMI) (kg/m2) 26.7 (23.9, 30.1)
Height (cm) 170 (163, 177)
Weight (kg) 77.9 (67.6, 89.2)
Smoking (%)
Nonsmoker 37.4
Exsmoker 34.7
Smoker 27.9
Diabetes mellitus type 2 (%) 7.4
Hypertension (%) 40.5
Metabolic syndrome (%) 23.4
Estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2) 88.5 (76.5, 102.4)
Left ventricle (LV) structural echocardiographic parameters
Left ventricular mass (LVM) (g) 172.4 (138.4, 211.7)
LVM index (LVMI) (g/m2) 90.5 (76.9, 106.5)
LV diameter during diastole (LVD) (cm) 4.9 (4.5, 5.2)
LV diameter during systole (LVS) (cm) 2.9 (2.6, 3.2)
Posterior wall diameter (PWD) (cm) 1.0 (0.9, 1.1)
Relative wall thickness (RWT) 0.4 (0.3, 0.4)
Left atrium (cm) 3.8 (3.5, 4.2)
Aorta (cm) 2.8 (2.5, 3.1)
LV systolic functional echocardiographic parameters
LV ejection fraction (LVEF) (%) 72 (66, 78)
Fractional shortening (%) 41 (36, 46)
LV diastolic functional echocardiographic parameters
Mitral valve (MV) E-wave (cm/s) 0.7 (0.6, 0.8)
MV A-wave (cm/s) 0.6 (0.5, 0.7)
MV duration A-wave (ms) 133 (121, 147)
MV deceleration (dec.) Time (ms) 179 (157, 203)
E/e ratio 5.9 (4.9, 7.1)
RV structural echocardiographic parameters
Right ventricle (RV) (cm) 2.4 (2.1, 2.8)
Right ventricular outflow tract (RVOT) (cm) 3.4 (3.0, 3.7)
RV systolic functional echocardiographic parameters
Tricuspid annular plane systolic excursion (TAPSE) (cm) 2.4 (2.1, 2.6)
Pulmonary valve (PV) acc. time (ms) 134 (115, 152)
PV acc. slope 5.8 (4.9, 7.1)
hArg (µmol/L)
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3.2. Association of hArg with Left Ventricular Structural Parameters
A one standard deviation (SD) decrease in serum hArg was associated with larger LVD
(0.3 95%-confidence interval [CI]: 0.2 to 0.5 mm; p < 0.001), LVS (0.38; 95%-CI: −0.22 to 0.54 mm;
p < 0.001) and lower RWT (−0.003 95%-CI: −0.0008 to −0.006; p = 0.01). No relations were found for
hArg and LVM, LVMI, PWD, left atrial, and aortic diameter (Table 2).
Table 2. The relation between hArg and cardiac structure and function. The outcomes were analyzed
by linear regression adjusted for sex, age, BMI, and eGFR. Bold lettering indicated p < 0.05.
β for 1 SD Decrease of hArg (95% CI) p
LV structural echocardiographic parameters
LVM (g) 1.29 0.0677(0.09, 2.67)
LVMI (g/m2)
0.63
0.0703(0.05, 1.31)
LVD (mm)
0.34
<0.0001(0.19, 0.50)
LVS (mm)
0.38
<0.0001(−0.22, 0.54)
PWD (mm)
−0.01
0.5514(−0.06, 0.03)
RWT
−0.003
0.011(−0.006,−0.001)
Left atrium (mm)
−0.07
0.3795(0.09, 0.24)
Aorta (mm)
0.07
0.2396(−0.05, −0.19)
LV systolic functional echocardiographic parameters
LVEF (%)
−0.47
0.0043(−0.79,−0.15)
Fractional shortening (%) −0.35 0.0141(−0.62,−0.07)
LV diastolic functional echocardiographic parameters
MV E-wave (mm/s)
−0.002
0.2607(−0.008, 0.002)
MV A-wave (mm/s)
−0.003
0.1708(−0.008, 0.001)
MV duration A-wave (ms)
0.41
0.2844(−0.34, 1.17)
MV dec. time (ms)
0.24
0.7166(−1.08, 1.57)
E/e ratio
−0.02 0.4205
(−0.08, 0.04)
RV structural echocardiographic parameters
RV (mm)
−0.0006
0.9422(−0.02, 0.02)
RVOT (cm)
0.01
0.07(−0.001, 0.03)
RV systolic functional echocardiographic parameters
TAPSE (cm)
−0.009
0.1772(−0.023, 0.004)
PV acc. time (ms)
0.39
0.3755(−0.48, 1.26)
PV acc. slope −0.04 0.1977(−0.12, 0.02)
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3.3. Association of hArg with Left Ventricular Functional Parameters
A one SD decrease in hArg was associated with less LVEF (−0.47 95%-CI: −0.79% to −0.15%;
p < 0.01) and FS (−0.35 95%-CI: −0.62% to −0.07%; p = 0.01). No relations were found for hArg and LV
diastolic functional parameters (i.e., E-wave, A-wave, A-wave duration, mitral valve deceleration time,
and E/e’ ratio; Table 2).
3.4. Assocation of hArg with Right Ventricular Parameters
We found no association between right ventricular structural (RV and RVOT), systolic functional
(TAPSE, PV acc. time, and PV acc. slope), and diastolic functional (TV S-wave, TV E-wave and TV
A-wave) parameters (Table 2).
3.5. Association of hARG with Biochemical Parameters (NTproBNP)
Low hArg was associated with higher NTproBNP −0.02 95%-CI: −0.034 to −0.009 log pg/mL;
p < 0.01) (Figure 1).
Figure 1. Relation between L-homoarginine (hArg) and N-terminal pro B-type natriuretic peptide
(NTproBNP). Low hArg was also related to higher NTproBNP (−0.02 95%-CI: −0.034 to −0.009 log
pg/mL; p < 0.01).
4. Discussion
This study assessed the relation between circulating hArg and echocardiographic parameters
as well as biochemical parameters of cardiac function in a large general population-based cohort.
Our findings support the notion for a positive association of hArg with cardiac health. Specifically,
we show that high hArg is related to lower left ventricular thickening, higher ejection fraction,
and lower NTproBNP. To our knowledge, this is the first report assessing the relation between
circulating hArg and a variety of echocardiographic parameters in more than 3000 subjects with
preserved or midrange ejection fraction.
Our results are in agreement with previous studies with regards to the inverse association
of hArg and NTproBNP. Specifically, in 3305 Caucasian patients who were referred for coronary
angiography examination at a tertiary care center in Germany and recruited to the Ludwigshafen
Risk and Cardiovascular Health (LURIC) study, hARG and NTproBNP were inversely associated [9].
Further support comes from the DIAST-CHF trial, in which patients with low hArg also had higher
NTproBNP values [6]. However, both of these studies assessed the relation between either hArg
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quartiles or severity of diastolic dysfunction, respectively. Nonetheless, a study in 1255 diabetic
hemodialysis patients also showed high NTproBNP concentrations in the lowest hArg quintile [11].
We extend their results by providing evidence that, even in the general population with NTproBNP
values mostly below clinical cut-offs, a strong inverse association between hArg and NTproBNP
is present.
With regard to left ventricular function, our results show a positive association between hArg
and LVEF as well as FS. This finding is also supported by the LURIC but not the DIAST-CHF results.
Specifically, LURIC patients in the lowest hArg quartile had a LVEF of 54% compared to 64% in the
highest quartile [9]. Interestingly, DIAST-CHF LVEF medians were always between 61% and 62%,
independent of hArg quartile [6]. The reason for this discrepancy may be related to the exclusion
criteria of DIAST-CHF trial, which excluded subjects with an LVEF < 50%. In our analysis, we included
midrange EF subjects and thus provided a large range of values for the regression analysis. A second
different finding between our results and the DIAST-CHF analysis is related to the lack of a relation
between hArg and diastolic function. However, since DIAST-CHF focused on subjects with diastolic
heart failure, our subject population may not have had a sufficient number of cases to detect a relation
between hArg and diastolic dysfunction.
Even though previous studies reported a relationship of hArg with LV systolic and diastolic
function, there is a knowledge gap regarding subclinical LV structural remodeling. However,
recent evidence from experimental mouse studies provides a first indication that low hArg may
contribute to impaired in vivo cardiac function, suggesting a potential role in the pathophysiology of
heart disease [7]. In our population-based cohort, low hArg was associated with more LV wall thickness
and lower LVEF. This finding may be interpreted as low levels of hArg being related with dilatation
of the heart and decreased function. Although the physiological function of hArg in the heart still
remains elusive, it may be related to the well-known cardioprotective effects of NO [24]. Specifically,
hArg increases NO bioavailability through at least two mechanisms. First, hArg is an alternative
substrate for NOS and inhibits arginases thereby increasing L-arginine availability [3,4]. However,
due to the low circulating concentrations of hArg, the physiological significance as an endogenous
metabolite of the NO pathway is currently unclear [24]. Secondly, hArg may be related to cellular
energy metabolism. Specifically, by its interference with AGAT, which is the first and rate-limiting
enzyme of creatine synthesis. After phosphorylation, creatine acts as a spatial and temporal cellular
energy buffer [25]. To date, AGAT is also considered the synthesizing enzyme of hArg in both
humans and mice [2,8] and hence linking hArg to energy metabolism [7]. Interestingly, AGAT and
the creatine/phosphocreatine system are downregulated in the failing heart [25,26]. A recent study
assessing the AGAT knockout mice demonstrated that not low creatine, but rather low hArg was the
driving force for cardiac dysfunction [7]. In our analysis, we specifically excluded subjects with heart
failure and reduced ejection fraction, yet our results confirm a potentially adverse cardiac remodeling
in subjects with low hArg.
Even though SHIP comprises a large and methodologically rigorous regionally representative
survey of northern Germany, the findings of our analyses need to be interpreted in the context of
several limitations. First, our analysis consisted of middle-aged Europeans living in rural areas.
Therefore, we do not know whether our findings are also applicable to other ethnicities or age
groups. Second, we used cross-sectional data from one time point. Hence, we do not know whether
increases in hArg are also associated with improved left ventricular structure and function. Third,
although we used a directed acyclic graph to identify metabolic and cardiovascular confounders for
our multivariable models, we cannot exclude the possibility of further residual confounding. Fourth,
the clinical interpretation of our results is difficult, as only ten subjects had heart failure with preserved
ejection fraction. A recent Mendelian randomization analysis concluded that even though low hArg
was associated with an increased risk for future hyperglycemias and abdominal obesity, there was
no evidence for any causal relation [27]. Since our study was a cross-sectional association analysis,
we cannot draw any causal conclusions based on our results. Hence, more experimental studies are
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necessary to improve our understanding of hArg biology. Irrespective of these limitations, strengths of
our study are the population-based setting, the large number of individuals, the use of standardized
data collection methods, the capacity to perform adjustment for a variety of clinical risk factors, and the
availability of a standardized echocardiographic examination from a large number of participants.
5. Conclusions
Our cross-sectional analyses showed that high levels of circulating hArg in a population-based
setting are associated with preferable left ventricular structure and function. We add new information
with regards to LV structural remodeling. Of note, we have previously reported serum reference
intervals for hArg, allowing the identification of individuals that might benefit from supplementation
with hArg to normalize serum concentrations and, in addition, may support cardiac health [16].
Completed and ongoing supplementation studies in mice and humans might improve our knowledge
of hArg metabolism and its mode of action [28,29].
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